The cathepsin K (CatK) inhibitor odanacatib (ODN) is currently being developed for the
treatment of osteoporosis. In clinical trials, efficacy and resolution of effect of ODN treatment …

Odanacatib (ODN) is a selective, potent and reversible inhibitor of cathepsin K (CatK) that
inhibits bone loss in postmenopausal osteoporosis. Evidence from osteoclast (OC) formation …

Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and
localized in the lysosomes and resorption lacunae of these cells. CatK is the principal …

Introduction: Osteoporosis and fragility fractures are important public health concerns.
Cathepsin K inhibitors, including odanacatib, are a novel class of medications for …

Cathepsin K is a key enzyme involved in the degradation of organic bone matrix by
osteoclasts. Inhibition of bone resorption observed in human and animal models deficient for …

Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐
blind, randomized, placebo‐controlled phase I studies, postmenopausal female subjects …

Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen.
Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone …

Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal
osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and …

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, was an investigational agent
previously in development for the treatment of osteoporosis. In this analysis, the effects of …

Merck & Co. has discontinued development of its cathepsin K inhibitor odanacatib, citing an
increased risk of cardiovascular events for the osteoporosis drug. The decision was an …